Neuromidine is a drug used in the treatment of a number of diseases of the central and peripheral nervous system.
Release form and composition
Neuromidin is available in two dosage forms:
- Tablets: white, round, flat-cylindrical, with a facet (in blister packs of 10 pcs .; 5 packs per carton);
- Solution for intramuscular and subcutaneous administration: colorless, transparent (in 1 ml glass ampoules; 5 ampoules in blisters; 2 packs in a carton box).
The composition of 1 tablet includes:
- Active ingredient: ipidacrine hydrochloride (as monohydrate) - 20 mg;
- Auxiliary components: calcium stearate - 1 mg; potato starch - 14 mg; lactose monohydrate - 65 mg.
The composition of 1 ml of solution includes:
- Active ingredient: ipidacrine hydrochloride (as monohydrate) - 5 or 15 mg;
- Auxiliary components: concentrated hydrochloric acid - up to pH 3.0; water for injection - up to 1 ml.
Indications for use
- Peripheral nervous system diseases: myasthenic syndrome of various etiologies, myasthenia, polyradiculopathy, poly-and mononeuropathy;
- Diseases of the central nervous system: the recovery period of organic lesions occurring with cognitive and / or motor impairment, bulbar paresis and paralysis;
- Atonia of the intestine (treatment and prevention; tablets).
- Bronchial asthma;
- Angina pectoris;
- Mechanical obstruction of the intestine or urinary tract;
- Severe bradycardia;
- Vestibular disorders;
- Peptic ulcer of the stomach or duodenum in the acute phase;
- Extrapyramidal diseases with hyperkinesis;
- Pregnancy and lactation;
- Age up to 18 years;
- Hypersensitivity to the drug.
Neuromidine should be used with caution in the presence of the following diseases / conditions:
- Acute respiratory diseases;
- Obstructive diseases of the respiratory system in history;
- Diseases of the cardiovascular system;
- Peptic ulcer and duodenal ulcer;
- Lactase deficiency, lactose intolerance, malabsorption isomaltose / lactose syndrome (tablets).
Dosing and Administration
The dosage of the drug and the duration of therapy is determined individually, depending on the severity of the disease.
Neuromidine is taken orally.
Recommended dosing regimen:
- Poly-and mononeuropathy, polyradiculopathy of various etiologies: 1 / 2-1 tablets 1-3 times a day for 1 to 2 months with a possible repetition of the course several times with intervals of 1-2 months;
- Severe disorders of neuromuscular conduction, as well as therapy to prevent myasthenic crises: 1-2 tablets 5 times a day (after short-term parenteral administration of 1-2 ml of 1.5% Neuromidine solution);
- Bulbar paresis and paralysis, recovery period of organic lesions of the central nervous system (vascular, traumatic and other genesis) occurring with cognitive and / or motor impairment: 1 / 2-1 tablet 2-3 times a day during the period from 2 to 6 months with possible repetition of the course of therapy;
- Intestinal atony (therapy and prevention): 1 tablet 2-3 times a day for 7-14 days.
If you skip taking the next dose of tablets, you should not take it in addition. The maximum dose is 200 mg per day.
Neuromidine is administered subcutaneously or intramuscularly.
Recommended dosing regimen:
- Poly-and mononeuropathy, polyradiculopathy of various etiologies: 5-15 mg 1-2 times a day for 10-15 days (in severe cases up to 30 days);
- Myasthenia gravis and myasthenic syndrome of various etiologies: 15-30 mg 1-3 times a day. The total duration of the course (injection solution and tablets) is 1-2 months with the possible repetition of the course several times with a break between them in 1-2 months;
- Bulbar paralysis and paresis: 5-15 mg 1-2 times a day for 10-15 days;
- Organic lesions of the central nervous system (rehabilitation): 10-15 mg of the solution intramuscularly 1-2 times a day for up to 15 days.
When applying the injection solution for all indications in the future, the patient is transferred to the reception of the drug inside.
During the use of Neuromidine, side effects develop in less than 10% of cases.
During therapy, it is possible to develop reactions caused by stimulation of m-cholinergic receptors, manifested as: heartbeat, drooling, sweating, jaundice, diarrhea, nausea, bradycardia, epigastric pain, convulsions, increased secretion of bronchial secretions (severity of bradycardia and salivation can be reduced m holinoblokatorami, for example, atropine).
When using Neuromidine in high doses, the following side effects may occur: headache, dizziness, chest pain, general weakness, vomiting, drowsiness, skin allergic reactions such as itching and rash (in these cases, reduce the applied dose or for a short time (1 2 days) interrupt the use of the drug).
Allergic reactions (in the form of skin manifestations) and an increase in the tone of the uterus may also develop during treatment.
In the application of Neuromidine should abandon the use of alcohol (due to the risk of the likelihood of side effects).
During therapy, it is recommended to refrain from driving a vehicle, as well as performing potentially hazardous types of work that require high concentration of attention and quick psychomotor reactions.
With the simultaneous use of Neuromidine with some drugs may develop the following effects:
- Medications that depress the central nervous system: increased sedation;
- Other cholinesterase inhibitors and m-cholinomimetic agents: enhancing the action and side effects of Neuromidine;
- Other cholinergics (in patients with myasthenia): an increase in the risk of a cholinergic crisis;
- Beta-blockers (when used prior to the initiation of Neuromidine therapy): increased risk of developing bradycardia;
- Local anesthetics, aminoglycosides, potassium chloride: weakening of the inhibitory effect on neuromuscular transmission and conduction of excitation along the peripheral nerves;
- Ethanol: increased side effects of Neuromidine.
Terms and conditions of storage
Store in a dark, dry place inaccessible to children at temperature up to 25 ° C.
- Pills - 3 years;
- Injection solution - 2 years.